65 related articles for article (PubMed ID: 12651263)
1. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Horne GA; Stobo J; Kelly C; Mukhopadhyay A; Latif AL; Dixon-Hughes J; McMahon L; Cony-Makhoul P; Byrne J; Smith G; Koschmieder S; BrÜmmendorf TH; Schafhausen P; Gallipoli P; Thomson F; Cong W; Clark RE; Milojkovic D; Helgason GV; Foroni L; Nicolini FE; Holyoake TL; Copland M
Leukemia; 2020 Jul; 34(7):1775-1786. PubMed ID: 31925317
[TBL] [Abstract][Full Text] [Related]
3. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
Ratajczak B; Przybyłowicz-Chalecka A; Czerwińska-Rybak J; Kanduła Z; Ustaszewski A; Gil L; Lewandowski K; Jarmuż-Szymczak M
Leuk Res; 2023 Sep; 132():107349. PubMed ID: 37393627
[TBL] [Abstract][Full Text] [Related]
4. Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia.
Guevara G; González JA; Lopera DE; González M; Saavedra JD; Lobaton JF; Duque JE
Colomb Med (Cali); 2012 Oct; 43(4):267-72. PubMed ID: 24893299
[TBL] [Abstract][Full Text] [Related]
5. Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate.
Srinivas BH; Paul TR; Uppin SG; Uppin MS; Jacob RT; Raghunadharao D
Indian J Hematol Blood Transfus; 2012 Sep; 28(3):162-9. PubMed ID: 23997453
[TBL] [Abstract][Full Text] [Related]
6. Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients.
Clark SE; Marcum ZA; Radich J; Etzioni R; Basu A
J Oncol Pharm Pract; 2023 Nov; ():10781552231212207. PubMed ID: 37960888
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
Iezza M; Cortesi S; Ottaviani E; Mancini M; Venturi C; Monaldi C; De Santis S; Testoni N; Soverini S; Rosti G; Cavo M; Castagnetti F
Cells; 2023 Jun; 12(13):. PubMed ID: 37443737
[TBL] [Abstract][Full Text] [Related]
8. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population.
Kockerols CCB; Geelen IGP; Levin MD; Janssen JJWM; Berna Beveloo H; Dinmohamed AG; Hoogendoorn M; Cornelissen JJ; Westerweel PE
Haematologica; 2023 Nov; 108(11):3156-3159. PubMed ID: 36951166
[No Abstract] [Full Text] [Related]
9. DNA Fingerprint Analysis of Raman Spectra Captures Global Genomic Alterations in Imatinib-Resistant Chronic Myeloid Leukemia: A Potential Single Assay for Screening Imatinib Resistance.
Mojidra R; Hole A; Iwasaki K; Noothalapati H; Yamamoto T; C MK; Govekar R
Cells; 2021 Sep; 10(10):. PubMed ID: 34685486
[TBL] [Abstract][Full Text] [Related]
10. High-risk additional chromosomal abnormalities at low blast counts herald death by CML.
Hehlmann R; Voskanyan A; Lauseker M; Pfirrmann M; Kalmanti L; Rinaldetti S; Kohlbrenner K; Haferlach C; Schlegelberger B; Fabarius A; Seifarth W; Spieß B; Wuchter P; Krause S; Kolb HJ; Neubauer A; Hossfeld DK; Nerl C; Gratwohl A; Baerlocher GM; Burchert A; Brümmendorf TH; Hasford J; Hochhaus A; Saußele S; Baccarani M;
Leukemia; 2020 Aug; 34(8):2074-2086. PubMed ID: 32382082
[TBL] [Abstract][Full Text] [Related]
11. Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Ma CC; Chai Y; Chen HL; Wang X; Gao Y; Hu WL; Xiang X
J Int Med Res; 2020 May; 48(5):300060520919237. PubMed ID: 32366154
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
Bavaro L; Martelli M; Cavo M; Soverini S
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817512
[TBL] [Abstract][Full Text] [Related]
13. Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia.
Krishna Chandran R; Geetha N; Sakthivel KM; Suresh Kumar R; Jagathnath Krishna KMN; Sreedharan H
Front Oncol; 2019; 9():88. PubMed ID: 30891424
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of cytogenetic monitoring in chronic myeloid leukemia].
Pan CY; Xu N; He BL; Cao R; Liao LB; Yin CX; Lan YQ; Lu ZY; Huang JX; Sun J; Feng R; Liu QF; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):112-117. PubMed ID: 28279034
[No Abstract] [Full Text] [Related]
15. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
[TBL] [Abstract][Full Text] [Related]
16. Studying the Impact of Presence of Alpha Acid Glycoprotein and Protein Glycoprotein in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate in the State of Qatar.
Al-Dewik NI; Jewell AP; Yassin MA; Morsi HM
Biomark Cancer; 2015; 7():63-7. PubMed ID: 26640393
[TBL] [Abstract][Full Text] [Related]
17. Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans.
Aïssata TD; Sawadogo D; Nanho C; Kouakou B; Meité N; Emeuraude N; Roméo A; Yassongui Mamadou S; Kouéhion P; Mozart K; Koffi G; Sanogo I
Adv Hematol; 2013; 2013():901589. PubMed ID: 23802015
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.
von Bubnoff N
Ther Adv Hematol; 2011 Apr; 2(2):95-110. PubMed ID: 23556080
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
[TBL] [Abstract][Full Text] [Related]
20. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.
Sherrill B; Kaye JA; Sandin R; Cappelleri JC; Chen C
Onco Targets Ther; 2012; 5():287-96. PubMed ID: 23109809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
